Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Other Non Operating Income: 2015-2024

Historic Other Non Operating Income for ImmunityBio (IBRX) over the last 10 years, with Dec 2024 value amounting to $13.5 million.

  • ImmunityBio's Other Non Operating Income fell 82.09% to $289,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$47.0 million, marking a year-over-year decrease of 334.69%. This contributed to the annual value of $13.5 million for FY2024, which is 706.25% up from last year.
  • According to the latest figures from FY2024, ImmunityBio's Other Non Operating Income is $13.5 million, which was up 706.25% from -$2.2 million recorded in FY2023.
  • ImmunityBio's 5-year Other Non Operating Income high stood at $13.5 million for FY2024, and its period low was -$2.2 million during FY2023.
  • Its 3-year average for Other Non Operating Income is $3.5 million, with a median of -$736,000 in 2022.
  • Per our database at Business Quant, ImmunityBio's Other Non Operating Income plummeted by 481.35% in 2022 and then surged by 706.25% in 2024.
  • Yearly analysis of 5 years shows ImmunityBio's Other Non Operating Income stood at $1.5 million in 2020, then tumbled by 87.01% to $193,000 in 2021, then slumped by 481.35% to -$736,000 in 2022, then tumbled by 202.04% to -$2.2 million in 2023, then surged by 706.25% to $13.5 million in 2024.